Short-term Outcomes of Switching from Bevacizumab to the Ranibizumab Biosimilar CKD-701 in Retinal Vein Occlusion

Purpose: This retrospective study compared outcomes in patients with macular edema secondary to retinal vein occlusion (RVO) who were switched from bevacizumab to the ranibizumab biosimilar CKD-701.Methods: We analyzed the medical records of patients who received CKD-701 injections for the treatment of macular edema secondary to RVO and who had previously been treated with bevacizumab.The best-corrected visual acuity (BCVA) and central retinal thickness (CRT) measured by optical coherence tomography were compared at two time points: before and one month after the last bevacizumab injection, and before and one month after the first CKD-701 injection.Treatment response was based on the degree of resolution of intraretinal fluid and subretinal fluid as good (3 points), partial (2 points), and poor (1 point), and the differences were analyzed statistically.Results: A total of 33 eyes from 33 patients were included, with a mean age of 70.93 ± 11.36 years.Both bevacizumab and CKD-701 significantly improved BCVA (p = 0.001 and p = 0.002, respectively).Similarly, both agents led to a significant reduction in CRT (p < 0.001 for each).The magnitude of CRT reduction (p = 0.367) and BCVA improvement (p = 0.474) did not differ significantly between the two treatment groups.When comparing treatment responses, one eye showed a poorer response with CKD-701, five eyes showed better responses, and 27 eyes showed similar outcomes.However, this difference was not statistically significant (p = 0.102).Conclusions: CKD-701 may serve as an effective alternative treatment option for RVO-related macular edema.